Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association Dor Cancer Research (AACR) Annual Meeting 2024
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association Dor Cancer Research (AACR) Annual Meeting 2024
Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73/PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC)
摘要將包括幾種藥物-FC偶聯物（DFC）候選藥物的臨床前數據，包括多特異性CD73/PD-1 DFC、靶向 DFC 的 CCR5 和 CBO421（CD73 靶向 DFC）
SAN DIEGO, March 06, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting three abstracts and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.
聖地亞哥，2024年3月6日——使用其專有Cloudbreak的生物技術公司Cidara Therapeutics, Inc.（納斯達克股票代碼：CDTX） 開發藥物-FC偶聯物（DFC）免疫療法的平台今天宣佈，該公司將在2024年4月5日至10日在加利福尼亞州聖地亞哥的聖地亞哥會議中心舉行的美國癌症研究協會（AACR）年會上發表三份摘要和一份最新摘要。
Presentation details are summarized below:
演示詳情總結如下：
Abstract Title: Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model
Presenter: James Levin, Ph.D.
Session Category: Immunology
Session Title: Single Target and Bispecific Antibodies
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Poster Board Number: 19, Section 6
摘要標題：發現一種多特異性CD73/PD-1靶向藥物Fc偶聯物（DFC），與人源化小鼠模型中的PD-1單一療法相比，該藥物可改善腫瘤減少率
主持人：詹姆斯·萊文博士
會議類別：免疫學
會議標題：單靶和雙特異性抗體
日期和時間：太平洋時間 2024 年 4 月 8 日星期一下午 1:30-5:00
海報板編號：19，第 6 節
Abstract Title: CBO421: A novel drug Fc-conjugate to prevent tumor immune evasion via the CD73/adenosine pathway
Presenters: Amanda Almaguer and Doug Zuill
Session Category: Immunology
Session Title: Immune Checkpoints and Inhibitory Molecules 2
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Poster Board Number: 22, Section 4
摘要標題：CBO421：一種通過 CD73/腺苷途徑防止腫瘤免疫逃避的新藥物 FC 偶聯物
主持人：阿曼達·阿爾瑪格爾和道格·齊爾
會議類別：免疫學
會議標題：免疫檢查點和抑制分子 2
日期和時間：太平洋時間 2024 年 4 月 8 日星期一下午 1:30-5:00
海報板編號：22，第 4 節
Abstract Title: CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
Presenter: Simon Döhrmann, Ph.D.
Session Category: Immunology
Session Title: Single Target and Bispecific Antibodies
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Poster Board Number: 22, Section 6
摘要標題：CCR5-001 是一種靶向 CCR5 的新型藥物 Fc-Conjougate (DFC)，在結直腸癌小鼠模型中顯示出強大的療效
主持人：西蒙·多爾曼博士
會議類別：免疫學
會議標題：單靶和雙特異性抗體
日期和時間：太平洋時間 2024 年 4 月 8 日星期一下午 1:30-5:00
海報板編號：22，第 6 節
Abstract Title: CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalization
Presenters: Elizabeth Abelovski and Nicholas Dedeic, Ph.D.
Session Title: Late-Breaking Research: Immunology 2
Date and Time: Monday, April 8, 2024, 9:00 AM-12:30 PM PT
Poster Board Number: 19, Section 52
摘要標題：CBO421，一種新型藥物 FC 偶聯物，抑制 CD73 的酶活性並觸發 CD73 內化
主持人：伊麗莎白·阿別洛夫斯基和尼古拉斯·德迪奇博士
會議標題：最新研究：免疫學 2
日期和時間：太平洋時間 2024 年 4 月 8 日星期一上午 9:00 至下午 12:30
海報板編號：19，第 52 節
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak platform to develop novel drug-Fc conjugates (DFCs). These targeted immunotherapies offer the unique opportunity to create "single molecule cocktails" comprised of targeted small molecules and peptides coupled to a human antibody fragment (Fc). DFCs are designed to save lives and improve the standard of care for patients facing cancers and other serious diseases by inhibiting specific disease targets while simultaneously engaging the immune system. In addition, Cidara received FDA and EU approval for REZZAYO (rezafungin for injection), which it has licensed to multiple partners to commercialize in the U.S. and ex-U.S. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
關於 Cidara Therapeu
Cidara Therapeutics 正在使用其專有的 Cloudb 開發新型藥物-FC偶聯物（DFC）的平台。這些靶向免疫療法爲創建 “單分子混合物” 提供了獨特的機會，該混合物由靶向小分子和與人類抗體片段（Fc）耦合的肽組成。DFC旨在通過抑制特定疾病靶標的同時激活免疫系統來挽救生命並提高面臨癌症和其他嚴重疾病的患者的護理標準。此外，Cidara的REZZAYO（注射用雷扎芬金）獲得了美國食品藥品管理局和歐盟的批准，它已授權多個合作伙伴在美國和美國以外地區將其商業化。Cidara 總部位於加利福尼亞州聖地亞哥。欲了解更多信息，請訪問 www.cidara.com。
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
投資者聯繫人：
布萊恩·裏奇
生命科學顧問
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Veronica Eames
LifeSci Communications
(646) 970-4682
veames@lifescicomms.com
媒體聯繫人：
維羅妮卡·埃姆斯
LifeSci
(646) 970-4682
veames@lifescicomms.com
譯文內容由第三人軟體翻譯。